Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m) - Marshall, A; Levine, M; Hill, C (J Thromb Haemost, 2020)
et al.